Seattle Children’s Cancer and Blood Disorders Center is consistently ranked among the top 10 pediatric cancer centers in the nation by U.S. News & World Report. In 2024, youth who received stem cell transplants at Seattle Children’s had a 97% survival rate, as measured at 100 days or more post-transplant. The center’s physicians lead national research groups including the Children’s Oncology Group, the largest pediatric oncology consortium in the world, and its immunotherapy program works to harness the immune system to fight cancer while reducing side effects. The Ben Towne Center for Childhood Cancer and Blood Disorders Research studies the biology of childhood cancer and blood diseases, and partners with Seattle Children’s therapeutics division to develop and test next-generation cell and gene therapies. Seattle Children’s pediatric blood and marrow transplant program and non-malignant transplant program work with Seattle-based partner Fred Hutchinson Cancer Center, whose doctors pioneered stem cell transplantation, to expand transplant access and improve cure rates. Its cancer and blood disorders center inpatient unit spans two floors with 48 private rooms and around-the-clock coverage from board-certified acute care hematology-oncology specialists. The center’s cancer survivor program provides personalized education, clinical care and research opportunities to help patients stay healthy long after treatment ends.
